In this study, we evaluated the clinical efficacy of hemoadsorption using Efferon CT in an expanded cohort of patients with severe COVID-19 course resistant to anti-IL-6 therapies and required post-therapy MLV versus a matched control group with no hemoadsorption. The gene discussed is IL6; the disease is COVID-19.